Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ProHema-CB

Cell therapy · developed by Fate Therapeutics

Phase 1 Most advanced trial (none active)

FATE Developer

1 Registered trials

What is ProHema-CB?

ProHema-CB is a biological product administered as a single unit transplant.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy
Therapy area: Oncology
Developer: Fate Therapeutics (FATE)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02354417	Phase 1	Hematologic Malignancies	Terminated	FATE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hematologic Malignancies

Sources

ClinicalTrials.gov NCT02354417

Updated Oct 11, 2026. Something wrong or missing? Report it on the FATE page.

Follow FATE, the company behind ProHema-CB

See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FATE catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z